Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism
Nifedipine kinetics after ingestion of 20 mg slow release tablets were studied in 12 young, healthy, Mexican subjects. Plasma levels were determined by a nifedipine-specific HPLC assay. Levels rose after drug administration reaching a maximum concentration of 48.7 +/- 7.3 ng/ml in 2.1 +/- 0.7 h (mea...
Saved in:
Published in | Journal of clinical pharmacology Vol. 29; no. 9; p. 816 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
01.09.1989
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Nifedipine kinetics after ingestion of 20 mg slow release tablets were studied in 12 young, healthy, Mexican subjects. Plasma levels were determined by a nifedipine-specific HPLC assay. Levels rose after drug administration reaching a maximum concentration of 48.7 +/- 7.3 ng/ml in 2.1 +/- 0.7 h (mean +/- SEM). Concentrations then decayed with a terminal half-life of 16.9 +/- 3.1 hours. AUC was 526 +/- 62 ng h/ml. Five individuals were fast and seven were slow nifedipine metabolizers, according to the AUC criterion proposed by Kleinbloesem and coworkers. Individual AUC/Dose values from this and from other two studies on oral nifedipine kinetics in Mexicans were cumulated and the frequency histogram and probit analyses were performed (N = 30). A bimodal distribution was clearly observed. Fast and slow metabolizers were distinguished as those subjects with AUC/Dose values either lower or higher than 22.5 ng h/ml mg. Unlike European populations, it appears that slow metabolization is more frequent in Mexicans. Data strongly support the hypothesis of the existence of a polymorphism concerning nifedipine disposition kinetics due to genetic basis. |
---|---|
AbstractList | Nifedipine kinetics after ingestion of 20 mg slow release tablets were studied in 12 young, healthy, Mexican subjects. Plasma levels were determined by a nifedipine-specific HPLC assay. Levels rose after drug administration reaching a maximum concentration of 48.7 +/- 7.3 ng/ml in 2.1 +/- 0.7 h (mean +/- SEM). Concentrations then decayed with a terminal half-life of 16.9 +/- 3.1 hours. AUC was 526 +/- 62 ng h/ml. Five individuals were fast and seven were slow nifedipine metabolizers, according to the AUC criterion proposed by Kleinbloesem and coworkers. Individual AUC/Dose values from this and from other two studies on oral nifedipine kinetics in Mexicans were cumulated and the frequency histogram and probit analyses were performed (N = 30). A bimodal distribution was clearly observed. Fast and slow metabolizers were distinguished as those subjects with AUC/Dose values either lower or higher than 22.5 ng h/ml mg. Unlike European populations, it appears that slow metabolization is more frequent in Mexicans. Data strongly support the hypothesis of the existence of a polymorphism concerning nifedipine disposition kinetics due to genetic basis. |
Author | Chávez, F Castañeda-Hernández, G Hoyo-Vadillo, C Herrera, J E Moreno-Ramos, A Hong, E Vidal-Gárate, J |
Author_xml | – sequence: 1 givenname: C surname: Hoyo-Vadillo fullname: Hoyo-Vadillo, C organization: Depto. de Farmacología y Toxicología, Centro de Investigación y de Estudios Avanzados del I.P.N., Mexico City, Mexico – sequence: 2 givenname: G surname: Castañeda-Hernández fullname: Castañeda-Hernández, G – sequence: 3 givenname: J E surname: Herrera fullname: Herrera, J E – sequence: 4 givenname: J surname: Vidal-Gárate fullname: Vidal-Gárate, J – sequence: 5 givenname: A surname: Moreno-Ramos fullname: Moreno-Ramos, A – sequence: 6 givenname: F surname: Chávez fullname: Chávez, F – sequence: 7 givenname: E surname: Hong fullname: Hong, E |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/2808746$$D View this record in MEDLINE/PubMed |
BookMark | eNotj0FLwzAYhnOYzG36E4TgvTVJkzbxJkOnMNGDnkeafGGZbVKSbm7_3oE7vfDw8MA7R5MQAyB0T0lJCWEPu5IKwQpeE15SJVU5tqTiTJTHCZoRomjBGkKu0TznHSG05oJO0ZRJIhtez9Dhc6tTr0388QFGbzKODgfvwPrhTHDu4i9O0IHOgEfddjBiH_A7HL3RAed9uwMz5kfs9mncQsJw8BaCAexiwmcjHr3Vo48BD7E79TENW5_7G3TldJfh9rIL9P3y_LV8LdYfq7fl07owvJKiYEqIVre01twya0HxmlnlFOgaABpnG6O0Mq2SVUMbqCxtFCPESMu5BSnZAt39d4d924PdDMn3Op02l__sD5HPYrk |
CitedBy_id | crossref_primary_10_1016_0163_7258_93_90053_G crossref_primary_10_2165_00003088_200645100_00001 crossref_primary_10_1016_j_bbmt_2011_08_019 crossref_primary_10_1177_089719009200500605 crossref_primary_10_1002_j_1552_4604_1993_tb03934_x crossref_primary_10_3109_03602539409029789 crossref_primary_10_1021_acs_chemrestox_0c00361 crossref_primary_10_1177_00912700222011175 crossref_primary_10_1038_sj_ki_5000325 crossref_primary_10_1016_S0188_4409_99_00069_7 crossref_primary_10_1016_S0278_6915_02_00209_0 crossref_primary_10_1002_j_1552_4604_1997_tb04346_x crossref_primary_10_1080_1354750X_2020_1754913 crossref_primary_10_1016_S1570_0232_02_00573_1 crossref_primary_10_1111_j_1365_2125_1995_tb04534_x crossref_primary_10_1155_2020_5347918 crossref_primary_10_1002_bdd_2510110904 crossref_primary_10_1038_sj_leu_2401660 crossref_primary_10_3109_03639049209043693 crossref_primary_10_1097_00008571_200203000_00006 crossref_primary_10_1177_0091270003258170 crossref_primary_10_1007_BF00880154 crossref_primary_10_1111_j_1365_2125_1991_tb05552_x crossref_primary_10_1002_j_1552_4604_1992_tb03814_x |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1002/j.1552-4604.1989.tb03425.x |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 2808746 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GeographicLocations | Mexico |
GeographicLocations_xml | – name: Mexico |
GroupedDBID | --- .55 .GJ 05W 0R~ 123 18M 1CY 1OB 1OC 29K 33P 34G 39C 3O- 3SF 4.4 52U 52V 53G 5RE 8-1 A00 AAESR AAEVG AAHHS AANLZ AAONW AASGY AAWTL AAXRX AAYOK AAZKR ABCUV ABJNI ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFO ACGFS ACGOF ACIWK ACMXC ACPOU ACPRK ACXBN ACXME ACXQS ADBBV ADBTR ADEOM ADIZJ ADMGS ADOZA ADXAS AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUYR AFBPY AFFNX AFFPM AFGKR AFPWT AFRAH AHBTC AHMBA AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AUVAJ AVWKF AZFZN AZVAB BDRZF BFHJK BHBCM BMXJE BOGZA BRXPI C45 CAG CGR COF CS3 CUY CVF D-I DCZOG DPXWK DRFUL DRMAN DRSTM DU5 EBD EBS ECM EIF EJD EMOBN F5P FEDTE FUBAC G-S GODZA GWYGA H13 HF~ HGLYW HVGLF IAO IEA IHR INH INR IVC KBYEO LATKE LEEKS LH4 LOXES LSO LUTES LW6 LYRES M4V MEWTI MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM MY~ N9A NPM O66 O9- OVD P2P P2W PALCI PQQKQ R.K RIWAO RJQFR ROL SAMSI SUPJJ SV3 TEORI VH1 WBKPD WH7 WIH WIJ WIK WOHZO WOIKV WPGGZ WXSBR WYJ X7M YCJ ZGI ZXP ZZTAW |
ID | FETCH-LOGICAL-c4385-2955bab16a4d2dde9462d9f9ea6eee7fd7c9a9cb983717e3d179200c8d44de882 |
ISSN | 0091-2700 |
IngestDate | Sat Sep 28 08:32:23 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 9 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c4385-2955bab16a4d2dde9462d9f9ea6eee7fd7c9a9cb983717e3d179200c8d44de882 |
PMID | 2808746 |
ParticipantIDs | pubmed_primary_2808746 |
PublicationCentury | 1900 |
PublicationDate | September 1989 |
PublicationDateYYYYMMDD | 1989-09-01 |
PublicationDate_xml | – month: 09 year: 1989 text: September 1989 |
PublicationDecade | 1980 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Journal of clinical pharmacology |
PublicationTitleAlternate | J Clin Pharmacol |
PublicationYear | 1989 |
SSID | ssj0016451 |
Score | 1.5016754 |
Snippet | Nifedipine kinetics after ingestion of 20 mg slow release tablets were studied in 12 young, healthy, Mexican subjects. Plasma levels were determined by a... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 816 |
SubjectTerms | Adult Chromatography, High Pressure Liquid Delayed-Action Preparations Humans Male Mexico Nifedipine - administration & dosage Nifedipine - blood Nifedipine - pharmacokinetics Oxidation-Reduction Phenotype Vasodilation - drug effects |
Title | Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism |
URI | https://www.ncbi.nlm.nih.gov/pubmed/2808746 |
Volume | 29 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6lIKReEK8KKKA9QC-pS2zver3cIAIipFY9pFVv1a53LEVt7SgP2vDz-GXMPmJbKRWPixV5E9vxfJqZncc3hLy1mZ3E5DziJsYNSiaKSJZaRAidkouk4APXX3F4lI1O2Lczftbr_exULS0X-qD48du-kv-RKp5Dudou2X-QbHNRPIGfUb54RAnj8a9kfBx4py_QVXR0y7YqY1KiPZpa53F-WV-7oShoqfoL2yPl5gEcwo3TffOltkEYVxNXLmfWE-xDGDIaiiv79c3ED12y0xxWVzVKZc05eNujbbospy0fdhOxH9WrOjpVZhKSPU10dqisBztM332KwahoBLPKZe_jdXS7mf6FSzOY-eLetoPiFJ_wMvrqf2OJL9pkl1Gb5VqNhpax7ZEbdDV0iIl4JMqOus19n-YtM-BpZdEMcJ4gAAfswN7LRsFTxKYvEO3gY3rlAJLkg1yw7I-LGwTdYWWLbInc6tgjGy8KeayMcT-zMfyrlvb2_d1Pt00ehGtu7HWczzN-RB4G0dKPHnmPSQ-qJ2QvoG61T8dt8958n-7R447cn5Lvm_CkdUlbeFILTxrgST086aSiAZ50Dc8PNICTrsFJEZwUv9GAk3bB-YycfPk8Ho6iMOYjKliKWiKRnGul40wxk6C1lSxLjCwlqAwARGlEIZUstMxTEQtIDdoQ1AJFbhgzgDvEHXKvqit4TigIJY2OAVhhmAQtIc8sp6YqFDr-On1Bdvz7PJ96Lpfz8KJf3rWwS7ZbmL4i90tUHfAa_dCFfuNE_QsTZIhf |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmacokinetics+of+nifedipine+slow+release+tablet+in+Mexican+subjects%3A+further+evidence+for+an+oxidation+polymorphism&rft.jtitle=Journal+of+clinical+pharmacology&rft.au=Hoyo-Vadillo%2C+C&rft.au=Casta%C3%B1eda-Hern%C3%A1ndez%2C+G&rft.au=Herrera%2C+J+E&rft.au=Vidal-G%C3%A1rate%2C+J&rft.date=1989-09-01&rft.issn=0091-2700&rft.volume=29&rft.issue=9&rft.spage=816&rft_id=info:doi/10.1002%2Fj.1552-4604.1989.tb03425.x&rft_id=info%3Apmid%2F2808746&rft_id=info%3Apmid%2F2808746&rft.externalDocID=2808746 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0091-2700&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0091-2700&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0091-2700&client=summon |